⚕️ Educational information only — not medical advice. Read the full disclaimer

Psoriatic Arthritis: Causes, Triggers and What Helps

Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthritis that develops in roughly one in five people with psoriasis. It is far more than "psoriasis plus sore joints": it can inflame the places where tendons and ligaments anchor to bone (entheses), swell a whole finger or toe, involve the spine, pit and lift the nails, and travel with gut and eye inflammation. This page explains what drives it — the IL-23/IL-17 immune axis, genes, obesity, mechanical stress and possibly the gut — with honest evidence grading, and explains why early rheumatology referral matters, how doctors screen for and classify PsA, how modern treatment is organized, and which lifestyle measures have real evidence behind them.

Important: This page is general educational information, not medical advice. Psoriatic arthritis must be diagnosed and managed by a qualified clinician, usually a rheumatologist working with a dermatologist. Always consult a healthcare professional before changing your diet, supplements, exercise, or medication, and never stop or change a prescribed medication without speaking to your doctor or pharmacist.

Key takeaways

  • About 19.7% of people with psoriasis have PsA (pooled across 266 studies); psoriasis usually comes first.3 Strong
  • PsA is driven by the IL-23/IL-17 and TNF pathways, with inflammation often starting at the enthesis; drugs that block these cytokines work.27 Strong
  • Damage can come quickly: 47% of an early-arthritis cohort had erosions at about two years, and even a 6-month delay in seeing a rheumatologist was linked to more erosions.424 Strong
  • Obesity raises the risk of PsA, and losing ≥5% of body weight was linked to better treatment response.1415 Strong (risk) Emerging (weight loss)
  • The smoking paradox (smoking looking "protective" in people with psoriasis) is most likely a statistical artefact; smoking raises PsA risk in the general population.17 Contested
  • Gut links (Crohn's disease overlap, altered microbiome) are real but the "leaky gut causes PsA" story is not proven.1213 Emerging
  • If you have psoriasis, annual screening (for example the PEST questionnaire) and prompt referral for swollen joints, "sausage" digits or heel pain are recommended.23 Strong

What psoriatic arthritis is Strong

PsA is a chronic inflammatory disease of the joints and entheses — the attachment points of tendons, ligaments and joint capsules to bone — including those of the spine. It belongs to the spondyloarthritis family alongside ankylosing spondylitis and arthritis linked to inflammatory bowel disease. Beyond the joints it can involve the skin and nails, cause dactylitis, uveitis (eye inflammation) and osteitis, and it is associated with higher cardiovascular risk.12

Unlike rheumatoid arthritis, PsA is usually negative for rheumatoid factor and anti-CCP antibodies, is often asymmetrical, and commonly affects the joints at the ends of the fingers (DIP joints) — which is why it is sometimes confused with hand osteoarthritis.1 For a side-by-side view, see where gout and PsA fit next to RA and OA.

19.7%of people with psoriasis have PsA (pooled, 266 studies)3
47%of an early-PsA cohort had erosions at ~2-year follow-up4
7.6%of first-degree relatives of people with PsA also had PsA5
≥40%have only a partial or no response to a given targeted drug2

How common is it in psoriasis? Strong

Estimates once ranged wildly. A 2019 systematic review and meta-analysis pooled 266 studies covering 976,408 people with psoriasis and found a PsA prevalence of 19.7% (95% CI 18.5–20.9%). It was 22.7% in European, 19.5% in North American and 14.0% in Asian patients, 23.8% in studies using the CASPAR criteria, and only 3.3% in children and adolescents. New cases arose at 0.27–2.7 per 100 person-years.3

In most people the skin disease comes first: in an Irish early-arthritis clinic, 119 of 129 people with PsA already had psoriasis when the arthritis was diagnosed.4 A U.S. population-based study (Rochester, Minnesota) found lower figures for clinically recognized PsA — a cumulative incidence of 1.7%, 3.1% and 5.1% at 5, 10 and 20 years after psoriasis began — and identified three skin features that predicted it: scalp psoriasis (HR 3.89), nail dystrophy (HR 2.93) and intergluteal/perianal psoriasis (HR 2.35).6 The gap between these numbers is itself a message: much PsA goes unrecognized unless someone looks for it.

The IL-23/IL-17 axis Strong

PsA sits on the same immune pathway as skin psoriasis. Cytokine-blocking drugs aimed at TNF and, more recently, the interleukin-23 / T-helper-17 pathway have been highly effective across several tissues, although blocking IL-23/IL-17 may work better in skin than in joints, and at least 40% of patients respond only partly to any one drug.2

Mechanism: why the enthesis?

In a landmark 2012 Nature Medicine study, Sherlock and colleagues found a previously unknown population of IL-23-receptor-positive T cells living in the enthesis. When stimulated with IL-23, these resident cells released IL-17, IL-22 and other inflammatory mediators without needing to recruit cells from the blood. Simply raising IL-23 in mice reproduced spondyloarthritis — enthesitis and new bone formation at the enthesis, initially without synovitis — plus inflammation at the aortic root, which is built like an enthesis. IL-22 drove the bone-forming response.7 This helps explain why PsA erodes bone in some places yet builds new bone (spurs, fusion) in others.

The clinical payoff is that EULAR's 2023 recommendations list biologics targeting IL-12/23 (p40), IL-23 (p19), IL-17A and IL-17A/F, alongside TNF inhibitors, among the main options — with the choice guided by which domains (skin, joints, spine, gut, eyes) are active.8

Enthesitis, dactylitis, axial and nail disease Strong

Rheumatologists think of PsA in domains, and the GRAPPA 2021 recommendations are organized around them: peripheral arthritis, axial disease, enthesitis, dactylitis, skin psoriasis and nail psoriasis, plus related conditions such as uveitis and inflammatory bowel disease.9 In an early-arthritis clinic cohort of 129 people with PsA, 38% had peripheral enthesopathy, 39% had DIP-joint involvement and 10% had inflammatory spinal pain at presentation; among those with psoriasis, 67% had nail dystrophy.4

The main domains of psoriatic arthritis
DomainWhat it looks likeNotes
Peripheral arthritisSwollen, tender joints; often asymmetrical; finger-end (DIP) joints commonly involvedCan be oligoarticular (few joints) or polyarticular (many)
EnthesitisPain and tenderness where tendons insert: back of the heel (Achilles), sole (plantar fascia), elbow, kneeOften mistaken for "tendinitis" or overuse; may not show up on blood tests
DactylitisA whole finger or toe swollen like a sausageA CASPAR criterion; involves tendon sheaths and surrounding tissues
Axial diseaseInflammatory back or buttock pain, worse after rest, with morning stiffness; sacroiliitisUsually occurs alongside peripheral arthritis; the PEST questionnaire does not detect it23
Nail diseasePitting, lifting of the nail (onycholysis), thickening, crumblingNail dystrophy predicts PsA in people with psoriasis6
Related conditionsUveitis (painful red eye, blurred vision), inflammatory bowel diseaseInfluence drug choice8

Why the nail? One leading explanation is anatomical: the nail bed sits very close to, and is thought to be connected with, the enthesis of the extensor tendon at the finger-end joint, which would help explain why nail psoriasis and DIP arthritis so often travel together. This is a widely held model rather than a settled fact.

Genetics and HLA-B27 Strong (heritability) Emerging (gene-phenotype links)

PsA runs strongly in families. In a Toronto study examining 289 first-degree relatives of 100 people with PsA, 7.6% had PsA and 15.2% had psoriasis. The recurrence risk ratio for PsA was about 30 — meaning relatives were roughly 30 times more likely to have PsA than the general population — compared with about 8 for psoriasis.5

Much of that risk sits in the HLA class I genes. Different alleles appear to shape which kind of PsA a person gets: in an Irish cohort of 282 patients, HLA-B27 (B*27:05) was associated with enthesitis, dactylitis and symmetrical sacroiliitis, while B*08 was linked to joint fusion, deformity and asymmetrical sacroiliitis, and B*44 haplotypes to milder disease.11 These were exploratory findings that need replication.

Testing tip: HLA-B27 is not a diagnostic test for PsA. Most people with PsA do not carry it, and many people who carry it never develop arthritis. It may be ordered when axial disease is suspected. See autoimmune markers on the biomarkers page.

The gut-skin-joint axis Strong (IBD overlap) Emerging (microbiome)

The gut connection is one of the most interesting — and most over-sold — areas in PsA. What is reasonably solid:

  • Crohn's disease overlap. In more than 174,000 U.S. women from the Nurses' Health Studies, psoriasis was linked to a 3.86-fold higher risk of later Crohn's disease (but not ulcerative colitis), and the risk was higher still — RR 6.43 — in women with psoriasis plus PsA.13 Strong
  • A shifted microbiome. In a small sequencing study (16 people with new-onset, untreated PsA, 15 with skin psoriasis and 17 controls), both patient groups had less diverse gut bacteria. The PsA profile — with fewer Akkermansia, Ruminococcus and Pseudobutyrivibrio — resembled that seen in inflammatory bowel disease.12 Emerging
  • Treatment cross-talk. EULAR 2023 advises that inflammatory bowel disease, if present, should influence drug choice, with monoclonal TNF inhibitors proposed — one reason a rheumatologist will ask about gut symptoms.8 Strong

What is not established is that a "leaky gut" causes PsA, or that a specific test or supplement protocol can reverse it. The microbiome findings come from small, cross-sectional studies that cannot show which came first. Our leaky gut and arthritis page covers the wider spondyloarthritis-IBD link and what the evidence does and does not support.

Obesity and weight loss Strong (risk) Emerging (weight loss improves response)

Obesity is one of the clearest modifiable risk factors. In a UK primary-care cohort of 75,395 people with psoriasis, the risk of developing PsA rose with body mass index: relative risks were 1.09 for BMI 25–29.9, 1.22 for BMI 30–34.9 and 1.48 for BMI ≥35, compared with BMI under 25.14

Weight also affects how well treatment works. Two studies stand out:

  • In 138 overweight or obese people starting TNF blockers, losing ≥5% of body weight predicted reaching minimal disease activity (OR 4.20). Minimal disease activity was reached by 23.1%, 44.8% and 59.5% of those losing <5%, 5–10% and >10% respectively — a clear dose-response.15
  • In a Swedish intervention study, 41 people with PsA and a BMI of 33 or more followed a very low energy diet (640 kcal/day for 12–16 weeks, under medical supervision) while their medicines were held constant. Median weight loss was 18.6%, and the share in minimal disease activity rose from 29% to 54%, with improvements in joint counts, enthesitis, skin, CRP, pain and fatigue.16

Mechanism: fat as an immune organ — and as a load

Visceral fat is metabolically active and releases inflammatory signals; extra body weight also loads the entheses of the heels, knees and spine, which links obesity to the mechanical-stress model below. Both mechanisms are plausible; how much each contributes is not yet known.

Neither study was a large randomized trial, so the size of the benefit is uncertain. But the direction is consistent, and weight loss also lowers the cardiovascular risk that comes with PsA.29 Very low energy diets should only be done with medical supervision.

The smoking paradox Contested

Smoking is a well-known risk factor for psoriasis, yet several studies found that among people who already have psoriasis, smokers were less likely to develop PsA — for example, an odds ratio of 0.6 in a Toronto case-control study.18 That looked like smoking "protects" the joints.

A UK study of 6.65 million people explored why. In the general population, smoking was associated with a 27% higher risk of PsA (HR 1.27). Only when the analysis was restricted to people with psoriasis did the association flip (HR 0.91). Mediation analysis showed smoking's effect on PsA ran almost entirely through causing psoriasis, and modest unmeasured confounding was enough to reverse the sign — a classic statistical trap called index-event (collider) bias.17

Bottom line: smoking is not protective. It raises the risk of psoriasis (and so PsA overall) and adds to the cardiovascular risk already linked to PsA. If you smoke, ask your doctor or pharmacist about support to stop.

Alcohol Emerging

In 82,672 U.S. women followed for 14 years, cumulative alcohol intake of 30 g a day or more (roughly two to three standard drinks) was associated with a 4.45-fold higher risk of developing PsA compared with not drinking; light drinking was not associated with higher risk.19 The Toronto case-control study, by contrast, found no association between alcohol and PsA onset.18

Alcohol is also relevant once PsA is diagnosed: it can worsen psoriasis, adds to liver strain — especially important with methotrexate, which is commonly used in PsA — and adds calories. Talk to your doctor or pharmacist about safe limits with your specific medicines. See foods to avoid for alcohol in the wider arthritis context.

Mechanical stress and "deep Koebner" Emerging

The Koebner phenomenon is the long-recognized tendency of psoriasis to appear at sites of skin injury. The "deep Koebner" hypothesis proposes that something similar happens below the skin: repeated microdamage at high-stress entheses triggers inflammation in people primed by psoriasis genes. Several lines of evidence fit:

  • In a UK cohort of people with psoriasis, recorded physical trauma was associated with a 32% higher risk of developing PsA (HR 1.32), rising to HR 1.46 for bone and 1.50 for joint trauma. The same analysis found no increased risk of rheumatoid arthritis after trauma in the general population (HR 1.04).20
  • In the Toronto case-control study, lifting cumulative loads of at least 100 pounds an hour (OR 2.8), injuries (OR 2.1) and infections needing antibiotics (OR 1.7) were associated with PsA onset.18
  • Ultrasound showed thickened flexor-tendon pulleys in the fingers of people with PsA (68% of pulleys) compared with rheumatoid arthritis (17%) and healthy controls (8%), particularly after dactylitis — supporting "deep koebnerisation" at sites of high physical stress.10

This does not mean people with psoriasis should avoid exercise — the evidence suggests the opposite (see lifestyle). It does suggest paying attention to persistent heel, tendon or joint pain after injury or heavy repetitive loading, and building up training load gradually. The pain rule on our exercise page is a practical guide.

Diagnosis and the CASPAR criteria Strong

There is no single test for PsA. Diagnosis is clinical — based on history, examination, psoriasis (current, past or in the family), and sometimes imaging — and blood tests mainly help rule out other conditions. The CASPAR criteria were developed from an international study of 588 PsA cases and 536 controls. They are classification criteria (built for research), but are widely used as a clinical checklist.21

CASPAR classification criteria: inflammatory articular disease (joint, spine or enthesis) plus ≥ 3 points
FeaturePoints
Current psoriasis2
Personal history of psoriasis (if no current psoriasis)1
Family history of psoriasis (if no current or past psoriasis)1
Typical psoriatic nail dystrophy1
Negative rheumatoid factor1
Dactylitis (current or recorded by a rheumatologist)1
Juxta-articular new bone formation on X-ray of hand or foot1

In the development study, CASPAR had a specificity of 98.7% and sensitivity of 91.4%.21 Note that someone can meet the criteria with no skin psoriasis at all, through family history, nails, negative RF and dactylitis. Inflammatory markers such as CRP and ESR are often normal in PsA; see inflammatory markers and CRP vs ESR.

Screening: the PEST questionnaire Strong

Because so much PsA is missed, guidelines recommend actively looking for it. The UK NICE psoriasis guideline advises offering an annual assessment for PsA to everyone with psoriasis — especially in the first 10 years after psoriasis begins — using a validated tool such as the Psoriasis Epidemiology Screening Tool (PEST), and referring to a rheumatologist as soon as PsA is suspected. NICE also notes that PEST does not detect axial arthritis or inflammatory back pain.23

PEST is five simple yes/no questions, covering swollen joints, a previous arthritis diagnosis, nail pits, heel pain and a finger or toe that was completely swollen and painful without obvious cause. In its development study it had a sensitivity of 0.92 and specificity of 0.78, better than an older tool; the authors noted it needed further validation.22 It is a screening prompt, not a diagnosis — a positive result means "get examined", and a negative one does not rule PsA out if symptoms persist.

Practical tip: if you have psoriasis, mention joint, heel or back symptoms to your dermatologist or GP even if they seem minor or unrelated. Our flare tracker can help you record symptoms, morning stiffness and swollen digits to bring to the appointment.

Why early referral matters Strong

PsA was once thought to be a mild arthritis. Prospective data say otherwise. In the Dublin early synovitis clinic cohort, mean disease duration at presentation was under a year, yet 47% of patients had erosions in the hands or feet at a median follow-up of 24 months, and only 21% were in remission at two years.4

Delay matters. In 283 people with long-standing PsA, the median time from first symptoms to seeing a rheumatologist was a year, and only 30% were seen within six months. Being seen more than six months after symptom onset was associated with peripheral joint erosions (OR 4.25) and worse physical function (OR 2.2) years later.24 This mirrors the "window of opportunity" concept in rheumatoid arthritis.

Treatment overview (GRAPPA & EULAR) Strong

This section describes how guidelines organize treatment, so you can have an informed conversation with your rheumatologist. It is not a recommendation for any individual. Two major guideline sets are used internationally:

Key principles from GRAPPA 2021 and EULAR 2023 (summary)
TopicSummary
Overall approachGRAPPA: choose therapy that addresses all active domains (joints, spine, entheses, dactylitis, skin, nails, plus uveitis, IBD and comorbidities) through shared decision-making9
NSAIDsEULAR: as sole treatment only for mild PsA and in the short term8
Oral glucocorticoidsEULAR: not recommended8
Peripheral arthritis, first stepEULAR: rapid start of a conventional synthetic DMARD, with methotrexate preferred8
If the target is not reachedEULAR: start a biologic DMARD, with no preference among modes of action (TNF, IL-12/23, IL-23, IL-17)8
Significant skin psoriasisEULAR: favors biologics targeting IL-23 or IL-178
Predominant axial or entheseal diseaseEULAR: a separate algorithm applies8
JAK inhibitorsEULAR: mainly after a biologic has failed, taking risk factors into account8
IBD or uveitis presentEULAR: should influence drug choice; monoclonal TNF inhibitors proposed8
RemissionBoth address tapering in sustained remission — a decision made with your rheumatologist89
Do not stop or change PsA medicines on your own. Stopping a DMARD or biologic can lead to flares and joint damage, and some drugs need monitoring blood tests or care around infections, vaccines, pregnancy and surgery. Discuss side effects, cost or a wish to try a different approach with your rheumatologist, doctor or pharmacist. More general information is on the medications page.

Evidence-graded lifestyle measures

Lifestyle measures complement medical treatment; none has been shown to replace it. Here is what the PsA-specific evidence shows — including where it is weaker than often claimed.

Lifestyle measures for psoriatic arthritis and what the evidence shows
MeasureWhat the evidence showsEvidence
Weight loss (if overweight)Obesity raises PsA risk; ≥5% weight loss linked to more minimal disease activity on TNF blockers; supervised very low energy diet improved joints, entheses, skin and CRP141516Emerging
Mediterranean dietCross-sectional study of 211 patients: higher adherence associated with lower disease activity (DAPSA); cannot show cause and effect25Emerging
ExerciseRCT of 67 patients: 11 weeks of high-intensity interval training was well tolerated, did not worsen disease activity and reduced fatigue, but did not lower disease activity scores26Strong (safe) Emerging (disease effect)
Omega-3 fish oil24-week RCT (3 g/day, 145 patients): disease activity improved but not significantly more than olive-oil placebo; NSAID and paracetamol use fell significantly27Contested
Vitamin DVITAL trial: 2,000 IU/day for about 5 years reduced new autoimmune disease by 22% in older adults28, but with later-confirmed cases the effect was no longer significant and it faded after people stopped30; not a treatment trial for existing PsA (see vitamin D and arthritis)Contested
Not smokingSmoking raises psoriasis risk and PsA risk at population level; the "protective" paradox is likely bias17Strong
Limiting alcoholHeavy intake (≥30 g/day) associated with higher PsA risk in one large cohort; relevant to liver safety with some medicines19Emerging
Cardiovascular risk carePsA patients not on a DMARD had a 24% higher risk of major cardiovascular events after adjusting for traditional risk factors29Strong
Putting it together: a realistic plan is gradual weight loss if needed, a Mediterranean-style eating pattern (see the anti-inflammatory diet), regular movement that you build up slowly (see exercising in flares vs remission), not smoking, keeping alcohol low, and checking blood pressure, lipids and blood sugar. Ask your doctor before starting supplements — see supplements for the wider evidence.
Dietary & supplement note: Statements here about foods and dietary supplements have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent any disease.

Red flags: when to see a doctor Strong

Seek urgent, same-day medical care if you have:
  • a single hot, red, very swollen joint with fever or feeling unwell — infection must be ruled out, especially if you take immune-suppressing medicines;
  • a painful red eye, light sensitivity or blurred vision — possible uveitis, which needs prompt eye assessment;
  • fever, chills or signs of infection while on a biologic, JAK inhibitor or methotrexate;
  • new back pain with leg weakness, numbness, or loss of bladder or bowel control;
  • chest pain or breathlessness.

Book a prompt (non-emergency) appointment if you have psoriasis — or a family history of it — and:

  • one or more swollen joints, or a whole swollen finger or toe;
  • heel, sole, Achilles or other tendon pain without a clear injury, or that persists;
  • back or buttock pain that is worse after rest, eases with movement and comes with morning stiffness;
  • nail pitting or lifting together with joint symptoms;
  • persistent bloody diarrhea, abdominal pain or weight loss (possible inflammatory bowel disease).

Frequently asked questions

How many people with psoriasis develop psoriatic arthritis?

A 2019 meta-analysis of 266 studies and nearly one million people with psoriasis found a pooled prevalence of psoriatic arthritis of 19.7% — about one in five — rising to 23.8% in studies that used the CASPAR classification criteria. Psoriasis usually appears before the arthritis, often by years. Nail changes and scalp or intergluteal psoriasis are linked to a higher risk. This is educational information, not medical advice.

Can I have psoriatic arthritis if my blood tests are normal?

Yes. There is no blood test that diagnoses psoriatic arthritis. Rheumatoid factor and anti-CCP antibodies are usually negative, and CRP or ESR can be normal even with active disease. Diagnosis rests on a rheumatologist's examination, the history of psoriasis, and sometimes ultrasound, MRI or X-rays.

Does losing weight help psoriatic arthritis?

Obesity is linked to a higher risk of developing psoriatic arthritis. In a prospective study of people starting TNF blockers, losing at least 5% of body weight was associated with higher odds of reaching minimal disease activity, and an intervention study of a very low energy diet showed improvements in joints, enthesitis, skin and CRP. Weight loss supports, but does not replace, medical treatment.

Is psoriatic arthritis the same as rheumatoid arthritis?

No. Both are inflammatory arthritis, but psoriatic arthritis is linked to psoriasis, is often asymmetrical, commonly affects the finger-end joints, tendon and ligament attachments (enthesitis), whole swollen fingers or toes (dactylitis), the spine and the nails, and is usually negative for rheumatoid factor and anti-CCP. Treatment choices also differ by which domains are active.

When should someone with psoriasis see a rheumatologist?

Anyone with psoriasis who develops joint swelling, a whole swollen finger or toe, heel or tendon pain, or inflammatory back pain with morning stiffness should ask for assessment. The UK NICE psoriasis guideline advises annual screening with a validated tool such as the PEST questionnaire and referral to a rheumatologist as soon as psoriatic arthritis is suspected, because even a six-month delay has been linked to more joint erosions.

References

  1. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970. PubMed 28273019
  2. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391:2273–2284. PubMed 29893226
  3. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e19. PubMed 29928910
  4. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460–1468. PubMed 14523223
  5. Chandran V, Schentag CT, Brockbank JE, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis. 2009;68:664–667. PubMed 18524791
  6. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233–239. PubMed 19177544
  7. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells. Nat Med. 2012;18:1069–1076. PubMed 22772566
  8. Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706–719. PubMed 38499325
  9. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465–479. PubMed 35761070
  10. Tinazzi I, McGonagle D, Aydin SZ, et al. 'Deep Koebner' phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. Ann Rheum Dis. 2018;77:922–925. PubMed 29511028
  11. Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis. 2016;75:155–162. PubMed 25261574
  12. Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67:128–139. PubMed 25319745
  13. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis. 2013;72:1200–1205. PubMed 22941766
  14. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71:1273–1277. PubMed 22586165
  15. Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014;73:1157–1162. PubMed 23771989
  16. Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019;21:17. PubMed 30635024
  17. Nguyen UDT, Zhang Y, Lu N, et al. Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Ann Rheum Dis. 2018;77:119–123. PubMed 29102956
  18. Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63:1091–1097. PubMed 21560259
  19. Wu S, Cho E, Li WQ, Han J, Qureshi AA. Alcohol intake and risk of incident psoriatic arthritis in women. J Rheumatol. 2015;42:835–840. PubMed 25834201
  20. Thorarensen SM, Lu N, Ogdie A, et al. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2017;76:521–525. PubMed 27457510
  21. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673. PubMed 16871531
  22. Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27:469–474. PubMed 19604440
  23. National Institute for Health and Care Excellence (NICE). Psoriasis: assessment and management (CG153), recommendations 1.2.2 on assessment and referral for psoriatic arthritis. nice.org.uk/guidance/cg153
  24. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045–1050. PubMed 24525911
  25. Caso F, Navarini L, Carubbi F, et al. Mediterranean diet and psoriatic arthritis activity: a multicenter cross-sectional study. Rheumatol Int. 2020;40:951–958. PubMed 31605152
  26. Thomsen RS, Nilsen TIL, Haugeberg G, et al. Impact of high-intensity interval training on disease activity and disease in patients with psoriatic arthritis: a randomized controlled trial. Arthritis Care Res (Hoboken). 2019;71:530–537. PubMed 29882634
  27. Kristensen S, Schmidt EB, Schlemmer A, et al. Beneficial effect of n-3 polyunsaturated fatty acids on inflammation and analgesic use in psoriatic arthritis: a randomized, double blind, placebo-controlled trial. Scand J Rheumatol. 2018;47:27–36. PubMed 28303758
  28. Hahn J, Cook NR, Alexander EK, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452. PubMed 35082139
  29. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326–332. PubMed 25351522
  30. Costenbader KH, Cook NR, Lee IM, et al. Vitamin D and marine n-3 fatty acids for autoimmune disease prevention: outcomes two years after completion of a double-blind, placebo-controlled trial. Arthritis Rheumatol. 2024;76(6):973–983. PubMed 38272846